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Anti-HMGCR Autoantibodies in Juvenile Idiopathic
Inflammatory Myopathies Identify a Rare but Clinically
Important Subset of Patients
Sarah L. Tansley, Zoe E. Betteridge, Stefania Simou, Thomas S. Jacques, Clarissa Pilkington,
Mark Wood, Kishore Warrier, Lucy R. Wedderburn, and Neil J. McHugh, on behalf of the
Juvenile Dermatomyositis Research Group
ABSTRACT. Objective. We aimed to establish the prevalence and clinical associations of anti-HMG-CoA-reductase
(anti-HMGCR) in a large UK cohort with juvenile myositis.
Methods. There were 381 patients investigated for anti-HMGCR using ELISA.
Results. Anti-HMGCR autoantibodies were detected in 4 patients (1%). These children had no or
minimal rash and significant muscle disease. Muscle biopsies were considered distinctive, with
widespread variation in fiber size, necrotic fibers, and chronic inflammatory cell infiltrates; all had
prolonged elevation of creatine kinase and all ultimately received biologic therapies.
Conclusion. Anti-HMGCR in UK children with myositis are associated with severe disease that is
poorly responsive to standard treatment. (J Rheumatol First Release February 15 2017; doi:10.3899/
jrheum.160871)
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Necrotizing autoimmune myopathy (NAM) is a subgroup of
the idiopathic inflammatory myopathies that is defined by
common clinical and histopathological features. Patients
present with high creatinine kinase (CK) levels and often
profound weakness. On muscle biopsy, characteristic features
include myofiber necrosis, minimal endomysial, and perivas-
cular inflammatory infiltrate, and in some cases focal
endomysial fibrosis1. Despite little or no muscle inflam-
mation, NAM usually responds to immunomodulatory
therapy, highlighting that this is an immune-mediated
phenotype. It has been associated with 2 myositis-specific
autoantibodies: antisignal recognition peptide (anti-SRP) and
more recently anti-HMG-CoA-reductase (HMGCR).
Patients with anti-HMGCR–associated disease make up
about 6% of adult idiopathic inflammatory myopathy
cohorts2. In addition to NAM, anti-HMGCR antibodies are
associated with statins, an intriguing finding given that
HMGCR is the pharmacologic target of statins and is upreg-
ulated by statin use2. While statins are typically prescribed
to adult patients, anti-HMGCR has been reported in patients
with juvenile-onset NAM, but data are extremely limited3.
Further, 40%–70% of adults with anti-HMGCR–associated
NAM have no history of statin exposure, suggesting the
presence of alternative disease triggers2,3. We aimed to
establish the prevalence and clinical associations of
anti-HMGCR in a large UK juvenile idiopathic inflammatory
myositis (JIIM) cohort.
MATERIALS AND METHODS
Patients. Serum samples and matched clinical data were obtained from 381
patients with JIIM recruited to the UK Juvenile Dermatomyositis Cohort
and Biomarker Study described previously4. Ethical approval has been
obtained (Northeast-York Research Ethics Committee 01/3/022). Parental
consent and consent or age-appropriate assent was obtained in accordance
with the Declaration of Helsinki.
Autoantibody detection. Immunoprecipitation of all samples was performed
to determine the presence of myositis-specific and -associated autoanti-
bodies, as previously described5,6. The presence of anti-HMGCR was deter-
mined in all samples by ELISA using recombinant antigen, as previously
described7. Positive samples were confirmed by Western blotting (insuffi-
cient serum for patient 3). A further 48 juvenile healthy controls, 21 patients
with juvenile systemic lupus erythematosus, and 27 muscular dystrophy
were found to be negative for anti-HMGCR.
Immunofluorescence. Human epithelial cell line 2 indirect immunofluores-
cence was performed at 1:40 serum dilution for all anti-HMGCR–positive
samples according to the manufacturer’s instructions (Inova).
Muscle biopsy. Where tissue was available for reassessment, muscle biopsies
were processed, stained, and scored (using the International Juvenile
Dermatomyositis score tool) by an expert pediatric neuropathologist (TSJ)
blinded to clinical data8,9.
RESULTS
Anti-HMGCR autoantibodies were detected in 4 of the 381
patients (1%). None had a history of statin exposure.
Anti-HMGCR autoantibodies were not found in conjunction
with any other myositis-specific or -associated autoantibody.
All patients with anti-HMGCR had a cytoplasmic staining
pattern on immunofluorescence, and 2 had additional coarse
speckled nuclear staining.
While numbers were insufficient for statistical analysis,
based on Childhood Myositis Assessment Scores (CMAS)
and the physician’s global assessment of disease activity
visual analog scores (PGA), children with anti-HMGCR were
weaker and had greater disease activity (Table 1). Consistent
with previous reports in juvenile-onset disease, CK at presen-
tation was elevated in just 55.4% of patients10,11. Of those
patients with an elevated CK, the median value was 1039 IU/l
(415–4115.25), compared with 15,500 (12,000–25,250) for
those with anti-HMGCR.
Patient 1. A 4-year-old girl developed a relatively slow-onset
muscular weakness with a lowest-ever CMAS of 28 (0–53),
corresponding to a moderate degree of weakness12. CK at
presentation was 12,000. She had no rash. Muscle biopsy was
reported to be consistent with dermatomyositis (DM). Her
highest-ever PGA was 4.8 out of 10. She responded to initial
treatment with oral methotrexate (MTX) and steroids, but CK
remained elevated. Her disease flared (lowest CMAS of 33
with no rash and peak CK of 7000) when MTX was stopped
after a lengthy period of remission, following which
treatment was restarted with subcutaneous MTX alongside
oral prednisolone (PRED). She subsequently responded to
infliximab (IFX) and entered remission.
Patient 2. A 13.8-year-old girl presented with periorbital
puffiness and hyperpigmentation with progressive weakness
over 1–2 months. Her CK was found to be 44,000. She
received pulsed intravenous (IV) methylprednisolone with
some improvement. Muscle biopsy revealed a destructive
myopathy with inflammation and necrosis. One month later,
her CMAS score was 0, indicating very severe weakness. She
required nasogastric feeding. She received further pulses of
IV methylprednisolone, cyclophosphamide (CYC), and
subcutaneous MTX. Improvement in muscle power was
extremely slow, leading to concern that there may be an
additional underlying muscle disease. Further investigations,
including magnetic resonance imaging (MRI), electromyog-
raphy, and nerve conduction studies were consistent with
myositis. This patient was subsequently treated with azathio-
prine, rituximab (RTX), and further CYC before entering
remission with IFX.
Patient 3. An 11.8-year-old boy presented with a 6-month
history of evolving proximal muscle weakness. CK was
19,000. Lack of any rash prompted consideration of muscular
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Table 1. Summary of the characteristics of the 4 patients with anti-HMGCR autoantibodies compared with the remainder of the JIIM cohort. Patients with
anti-HMGCR were weaker, had more severe disease, and had dramatically higher CK levels throughout their disease course.
Patient Skin Sex Age at Lowest CMAS, Highest PGA, CK at Onset, CK at 6 Mos CK at 12 Mos Lowest CK, 
Rash Disease Onset, 0–53 0–10 IU/l Postdiagnosis, Postdiagnosis, IU/l
Yrs IU/l IU/l
1 No Female 4 28 4.8 12,180 1275 278 231
2 Minimal Female 13 0 8.3 44,002 404 13,065 251
3 No Male 11 36 3 19,000 4702 4038 1527
4 Minimal Female 9 2 9.5 12,662 2004 4638 2241
Median (IQR) for patients 
with anti-HMGCR 10.6 (7.5–12.3) 15 (1.8–30) 6.6 (4.4–8.6) 15,500 1057 4338 889 
(12,000–25,250) (1057–2679) (3098–6744) (246–1705.5)
Median (IQR) for all 
381 patients 6.8 (3.9–10.1) 40 (24–47.3) 4 (2.2–7) 225 (78–1191.5)a 65 (41–106)b 88 (60–114)c 53 (37–82.5)
a Median for those with a raised CK 1039 (415.4–115.25). b CK available between 4 and 8 months for 60 patients. c CK available between 10 and 14 months
for 48 patients. Anti-HMGCR: anti-HMG-CoA-reductase; JIIM: juvenile idiopathic inflammatory myositis; CK: creatine kinase; CMAS: Childhood Myositis
Assessment Score, 0–53; PGA: physician’s global assessment visual analog score of disease activity, 0–10; IQR: interquartile range.
dystrophy in the differential diagnosis, but electromyography
and muscle biopsy were most consistent with an inflam-
matory myositis. While clinically this patient’s myositis was
not severe (CMAS 30–36, consistent with mild to moderate
weakness and highest ever PGA 3), his CK has been persist-
ently elevated. The patient had a poor response to MTX and
ultimately responded clinically to RTX. CK remains > 1000.
Patient 4. A 9.4-year-old girl presented with a 4-month
history of progressive muscle weakness. An inflammatory
rash was confined to her antecubital fossae. CMAS was 2,
consistent with severe weakness. At presentation, alanine
aminotransferase was 600 U/l, lactate dehydrogenase 
4000 U/l, and CK 12,000. A liver biopsy was normal. MRI
showed widespread muscle edema. Following treatment with
IV methylprednisolone, PRED, and subcutaneous MTX,
CMAS remained between 5 and 30 (moderate to severe
weakness) and muscle enzymes were persistently elevated
with CK > 3000. Subsequent treatment included IFX, IV
immuno globulin (IG), mycophenolate mofetil (MMF), and
IV CYC. Her highest PGA was 9.5. The poor treatment
response ultimately prompted diagnostic reassessment with
muscle biopsy, skin biopsy, and weaning of all immunosup-
pression. The patient deteriorated without immunosup-
pression and PRED was reintroduced. Muscle biopsy showed
necrosis and inflammation, and while not typical was felt to
be consistent with myositis. Skin biopsy revealed inflam-
mation in the dermis favoring DM. Following confirmation
of anti-HMGCR status, the patient has been retreated with
IVIG and MMF with a slow, but clear improvement.
Muscle biopsy. Muscle biopsy material was available for
reassessment in 3 patients and the written report of the fourth
biopsy was also available. Biopsy score components are
shown in Table 2. The biopsies had similar and distinctive
features with widespread variation in fiber size, regenerating
fibers, necrotic fibers, and degenerating fibers. There were
frequent fibers expressing immature isoforms of myosin and
deposition of the membrane attack complex (MAC; C5b-C9)
on the sarcolemma of many fibers. There were patchy dense
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Table 2. Muscle biopsy score breakdown for patients with anti-HMGCR. Biopsy appearances were consistent with a destructive myopathy with high scores in
the muscle fiber domain. All biopsies had evidence of inflammation. Muscle biopsies were analyzed using the JDM muscle biopsy score tool as previously
described by Wedderburn, et al8,9.
Variables Patient 1 Patient 2 Patient 3 Patient 4
Any treatment prebiopsy? No Yes No Yes
Inflammatory domain
CD3+ endomysial infiltration, 0–2 2 No tissue available for histological reassessment.a 2 1
CD3+ perimysial infiltration, 0–2 0 1 0
CD3+ perivascular infiltration, 0–2 2 2 0
CD68+ endomysial infiltration, 0–2 2 2 1
CD68+ perimysial infiltration, 0–2 1 2 1
CD68+ perivascular infiltration, 0–2 2 2 1
Domain total 9 11 4
Vascular domain
Capillary dropout, 0–1 0 0 0
Arterial abnormality, 0–1 0 0 0
Infarction, 0–1 0 0 0
Domain total 0 0 0
Muscle fiber domain
MHC I over-expression, 0–1 1 1 0
Perifascicular atrophy 2 2 1
Neonatal myosin, 0–1 1 1 1
Fiber atrophy, 0–1 1 1 0
Regeneration/degeneration/necrosis perifascicular 2 2 2
Regeneration/degeneration/necrosis nonperifascicular 2 2 2
Internal myonuclei in nonbasophilic otherwise 
normal fibers, 0–1 1 1 1
Domain total 10 10 7
Connective tissue domain
Any endomysial fibrosis, 0–1 1 1 1
Any perimysial fibrosis, 0–1 0 1 0
Domain total 1 2 1
Total score, 0–27 20 23 12
VAS severity, 0–10 7 9 7
MAC (C5-9b) staining of necrotic fibers Yes Yes Yes
Significant data are in bold face. a Original muscle biopsy report comments on muscle fiber necrosis and inflammation. Biopsy findings were considered
supportive of a diagnosis of a myositis in the correct clinical context, but not diagnostic on their own. Anti-HMGCR: anti-HMG-CoA-reductase; JDM: juvenile
dermatomyositis; VAS: visual analog scale; MAC: membrane attack complex.
infiltrates of chronic inflammatory cells within the fascicles
(Figure 1).
DISCUSSION
Consistent with previous reports, patients with anti-HMGCR
presented with either profound or insidious onset muscle
weakness3. Unlike affected adults, however, half of our
patients had cutaneous disease2,3. Lack of skin involvement
is unusual in JIIM and minimal/absent rash contributed to the
need to actively exclude alternative diagnoses in those with
anti-HMGCR. Remarkably, all children with anti-HMGCR
underwent muscle biopsy and 2 electromyography; these
invasive procedures are not routinely used diagnostically in
the United Kingdom for suspected JIIM, the majority of
patients being diagnosed on the basis of clinical features plus
laboratory and MRI results.
Muscle biopsies were distinctive and features included
those previously reported by Allenbach, et al, with muscle
fiber necrosis and degeneration/regeneration3. Contrary to
previous reports of a pauciimmune necrotizing myopathy,
however, there was evidence of inflammation in all 4
biopsies. JIIM muscle biopsies can display a wide range of
changes that may not necessarily be considered “typical” of
DM. All patients with anti-HMGCR had an abnormal muscle
biopsy with a pattern of histological features that, while not
classic for DM, was consistent and distinctive. Recognition
of this phenotype is important to ensure that muscle biopsy
can provide the maximum level of diagnostic accuracy.
Earlier recognition of anti-HMGCR autoantibodies may aid
diagnosis, prevent potentially unnecessary investigations, and
facilitate rapid treatment escalation in the absence of a good
response to standard therapy. Mammen, et al confirmed the
absence of anti-HMGCR in patients with genetic muscle
diseases that often form the differential diagnosis13.
While rare, anti-HMGCR identify an important group of
JIIM patients with severe disease necessitating aggressive
treatment. In the United Kingdom, strict guidelines exist for
funding biologic treatments, and it is remarkable that all 4
cases ultimately received this; in comparison with just
20.7% of the total cohort. We noted similarities in disease
presentation to those patients with anti-SRP autoantibodies,
in whom muscle weakness is also greater and cutaneous
disease less common. Less than one-third of patients with
anti-SRP, however, required treatment with a biologic drug
and/or IV CYC. It is interesting to note that while statin-
exposed adult patients with anti-HMGCR are reported to
respond dramatically to treatment, statin-naive patients have
been noted to be younger, and may be refractory to immuno-
suppressive therapy2,14. Younger, statin-naive patients with
anti-HMGCR may represent a separate subgroup of patients
who are less responsive to treatment. These data suggest that
in those children with anti-HMGCR and severe weakness,
there is an argument for the early use of aggressive immuno-
suppression.
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Figure 1. Muscle biopsy features of patients with anti-HMGCR autoantibodies. All 3 biopsies showed a similar distinctive pattern of
pathology characterized by widespread variation in fiber size, regenerating fibers, necrotic fibers, and degenerating fibers with vacuoles
and ill-defined eosinophilic granules (A–C). The abnormal fibers were present throughout all the fascicles with no perifascicular
accentuation. There were patchy dense infiltrates of chronic inflammatory cells within the fascicles. The infiltrate showed a prominent
component made up of T lymphocytes (D; CD3). There were fewer inflammatory cells in the perimysium. In all 3 cases, many of the
fibers expressed a developmental isoform of myosin (E; NEO). Staining for the MAC (C5b-9) of the complement cascade highlighted
necrotic fibers, but also outlined the sarcolemma of many of the non-necrotic fibers (F). Capillary deposition of MAC was not seen.
Scale bars-100 µm. Anti-HMGCR: anti-HMG-CoA-reductase; NEO: neonatal myosin; MAC: membrane attack complex. 
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